10th Feb 2014 08:37
LONDON (Alliance News) - Oral and inhalation drug specialist Skyepharma PLC Monday said its had launched its flutiform asthma treatment in France after it got regulatory approval and a deal on pricing reimbursements.
In a statement, the company said the treatment will be marketed by Mundipharma in France, and Skyepharma will get a EUR3.0 million milestone payment plus royalties on net sales.
The news means that flutiform has now been approved in 22 countries, most recently Switzerland, and has been launched in 14 European countries.
"With the launch in France and the recent successful completion of the mutual recognition procedure for Spain, flutiform is now on track to be available in all of Europe's five largest markets, bringing more patients an effective treatment for asthma. We look forward to the further roll-out of flutiform and its continued growth," Skyepharma Chief Executive Peter Grant said in a statement.
Skyepharma shares were up 13% at 183 pence early Monday, one of the biggest gains on the London market.
By Steve McGrath; [email protected]; @SteveMcGrath1
Copyright © 2014 Alliance News Limited. All Rights Reserved.
Related Shares:
SKP.L